BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20251007T101004EDT-7257AGKtMA@132.216.98.100
DTSTAMP:20251007T141004Z
DESCRIPTION:Despite that NO is a small\, diatomic gas\, believed to be free
 ly-diffusible in cells\, its contrasting anti- and pro-tumour effects in m
 acrophages may be explained by our concept that it is not freely diffusibl
 e. In fact\, it may be tightly regulated by NO-storage and -transport prot
 eins\, i.e.\, glutathione-S-transferase-P1 (GSTP1) and multidrug resistanc
 e-associated protein 1 (MRP1). The pharmacology of this novel system is un
 clear and requires dissection to elucidate targets that can be therapeutic
 ally-exploited.\n\nThis seminar is dedicated to the late Dr. Prem Ponka.\n
 \nSpeaker biography:\n\nProfessor Des Richardson holds the Chair of Cancer
  Cell Biology at the University of Sydney\, Australia\, and is a National 
 Health and Medical Research Council (NHMRC) of Australia Senior Principal 
 Research Fellow. He is a multi-disciplinary pharmacologist whose career ha
 s spanned metabolism\, medicinal chemistry\, drug design/development/comme
 rcialization\, cancer biology\, and neurobiology.\n\nHe has published 421 
 articles\, reviews\, patents\, chapters etc.\, over his career with >93% a
 s first\, senior or corresponding author (H-index: 88\; >32\,400).\n\nHe i
 s Executive Editor of BBA-General Subjects and has served on the Ed. Board
 s of 45 journals\, including: JBC\, Antioxidants Redox Signaling\, Biochem
 . J.\, J. Clin. Pathology (Assoc. Ed.)\, Int. J. Biochem. Cell Biology – M
 olecules in Focus Editor (for 10 years)\, BBA-Mol Cell Res\, Mol. Pharmaco
 l.\, Pharmacol. Res.\, BBA-Reviews on Cancer\, etc.\n\nAs a major translat
 ional research achievement\, he has developed the anti-cancer and anti-met
 astatic drug\, DpC\, which overcomes P-glycoprotein-mediated drug resistan
 ce and up-regulates the potent metastasis suppressor\, NDRG1. This has led
  to commercialisation of DpC and the development of the international comp
 any\, Oncochel Therapeutics LLC\, USA and its Australian subsidiary\, Onco
 chel Therapeutics Pty Ltd. Notably\, DpC has entered multi-centre Phase I 
 clinical trials for the treatment of advanced and resistant cancer. These 
 anti-cancer drugs target the lysosome via the P-glycoprotein transporter.
 \n
DTSTART:20191113T160000Z
DTEND:20191113T170000Z
LOCATION:Room 1027\, McIntyre Medical Building\, CA\, QC\, Montreal\, H3G 1
 Y6\, 3655 promenade Sir William Osler
SUMMARY:Seminar - Intracellular and extracellular nitric oxide transport an
 d its role in M1 and M2 macrophages as a novel mechanism involved in tumor
  cell killing or promotion
URL:/physiology/channels/event/seminar-intracellular-a
 nd-extracellular-nitric-oxide-transport-and-its-role-m1-and-m2-macrophages
 -300882
END:VEVENT
END:VCALENDAR